Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)
  4. Volume 22, Issue 2
  5. Article
Volume 22, Issue 2
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Background

Advances in organ transplantation were made after the discovery of the pure form of cyclosporine by Dr Jean Borel in the 1970s. In fact, in clinical practice achieving a delicate balance in circulating immunosuppressive necessitate focus on the difficult task of post-transplant therapeutic drug monitoring.

Objective

The purpose of this study was to determine the pharmacologic properties of cyclosporine-tacrolimus, detection methods, and the effects on the activity of cytochrome P450 enzymes when prescribing the most efficient treatments in forms of polypharmacy for the recipients of heart transplantation.

Methods

Scientific literature on the interactions of tacrolimus and cyclosporine with human cytochrome P450 enzymes was searched using PUBMED.Gov (https://pubmed.ncbi.nlm.nih.gov/), Web of Science, and Scopus.

Results

Prescription immunosuppressive drugs based on polypharmacy accompanied by induction agents could result in hidden neurotoxicity and nephrotoxicity. A literature search shows that cyclosporine prescription with antihypertensives drugs needs close monitoring. Co-administration of tacrolimus and diltiazem or verapamil needs a decrease in the tacrolimus dose by 20-50%. Vigilant attention to the lowest possible statin dose is needed when coadministered with fluvastatin or pravastatin. Polypharmacy based on ticlopidine, clopidogrel, and cyclosporine or tacrolimus needs monitoring of immunosuppressive drug levels for several months. A prescription with clotrimazole or fluconazole needs close monitoring, and itraconazole or ketoconazole needs to reduce the initial dose by 50%. Combination with nefazodone needs to be avoided, and alternative drugs such as sertraline or citalopram could be prescribed in addition to further monitoring consideration. In prescription with phenytoin, the bound and free phenytoin levels need close monitoring.

Conclusion

Polypharmacy based on tacrolimus or cyclosporine needs vigilant therapeutic drug monitoring due to the cytochrome P450 enzymes associated with biochemical variables in metabolic pathways. Further attention to polypharmacy should be given to circulate drugs that could hide pharmacokinetics interactions associated with infections, malignancies, chronic kidney disease, and rejection after organ transplantation.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/1871525721666230726150021
2024-06-01
2024-11-22

  • From This Site

    /content/journals/chamc/10.2174/1871525721666230726150021
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HarrisC. CaoC. CroceB. Munkholm-LarsenS. Heart transplantation.Ann. Cardiothorac. Surg.20187117210.21037/acs.2018.01.1129492396
     [Google Scholar]
  2. BarnardC.N. The operation. A human cardiac transplant: An interim report of a successful operation performed at groote schuur hospital, cape town.S. Afr. Med. J.19674148127112744170370
     [Google Scholar]
  3. Tolou-GhamariZ Mir Mohammad SadeghiM MazdakH. Monitoring heart transplant recipients in order to investigate immunosuppressive drug absorption using pharmacokinetics parameters and its’ correlation with nephrotoxicity.AJECR201964
     [Google Scholar]
  4. Tolou-GhamariZ. PalizbanA.A. Michael TredgerJ. Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoassay.Drugs R D.200451172210.2165/00126839‑200405010‑0000314725486
     [Google Scholar]
  5. KirubakaranR. UsterD.W. HennigS. CarlandJ.E. DayR.O. WichaS.G. StockerS.L. Adaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients.Br. J. Clin. Pharmacol.20238931162117510.1111/bcp.1556636239542
     [Google Scholar]
  6. RegazziM.B. RinaldiM. MolinaroM. PellegriniC. CalviM. ArbustiniE. BellottiE. BascapèV. MartinelliL. ViganòM. Clinical pharmacokinetics of tacrolimus in heart transplant recipients.Ther. Drug Monit.19992112710.1097/00007691‑199902000‑0000210051048
     [Google Scholar]
  7. KaltD.A. Tacrolimus: A review of laboratory detection methods and indications for use.Lab. Med.2017484e62e6510.1093/labmed/lmx05629096030
     [Google Scholar]
  8. YangX. GuoC. ZhangM. LiY. RenM. MaoS. DhakalR. KimN.Y. DongZ. SunB. YaoZ. Ultrahigh-sensitivity multi-parameter tacrolimus solution detection based on an anchor planar millifluidic microwave biosensor.Anal. Methods202315141765177410.1039/D3AY00100H36880531
     [Google Scholar]
  9. HuoY. ZhangS. PanC. ShanH. XuY. CaiX. A robust procedure for determination of immunosuppressants cyclosporine a and tacrolimus in blood samples with detection of LC–MS/MS.Chromatographia202386325526310.1007/s10337‑023‑04241‑8
     [Google Scholar]
  10. HuangY. TangH. MengX. ZhongH. SongY. ChenB. ZouZ. Rapid and simultaneous determination of two immunosuppressants in whole blood by high performance liquid chromatography.Se Pu202341215215910.3724/SP.J.1123.2022.03033
     [Google Scholar]
  11. WangX. DaiX. WanS. FanY. WuL. XuH. YanL. GongX. LiY. LuoY. BaiY. LiY. A volumetric absorptive microsampling uplc-ms/ms method for simultaneous quantification of tacrolimus, mycophenolic acid and creatinine in whole blood of renal transplant recipients.Pharmaceutics20221412254710.3390/pharmaceutics1412254736559041
     [Google Scholar]
  12. KawaiT. MiharaY. MoritaM. OhkuboM. AsamiT. WatanabeT.M. Quantitation of cell membrane permeability of cyclic peptides by single: Cell cytoplasm mass spectrometry.Anal. Chem.20219373370337710.1021/acs.analchem.0c0390133550808
     [Google Scholar]
  13. LeeY.W. Comparison between ultra-performance liquid chromatography with tandem mass spectrometry and a chemiluminescence immunoassay in the determination of cyclosporin a and tacrolimus levels in whole blood.Exp. Ther. Med.2013661535153910.3892/etm.2013.132524255687
     [Google Scholar]
  14. TszyrsznicW. BorowiecA. PawlowskaE. JazwiecR. ZochowskaD. BartlomiejczykI. ZegarskaJ. PaczekL. DadlezM. Two rapid ultra performance liquid chromatography/tandem mass spectrometry (uplc/ms/ms) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.201392891510.1016/j.jchromb.2013.03.01423584041
     [Google Scholar]
  15. CrettolS. VenetzJ.P. FontanaM. AubertJ.D. PascualM. EapC.B. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.Ther. Drug Monit.200830668969910.1097/FTD.0b013e31818a2a6018978522
     [Google Scholar]
  16. BarbarinoJ.M. StaatzC.E. VenkataramananR. KleinT.E. AltmanR.B. PharmGKB summary.Pharmacogenet. Genomics2013231056358510.1097/FPC.0b013e328364db8423922006
     [Google Scholar]
  17. Tolou-GhamariZ. Monitoring tacrolimus after liver transplanatation; a consideration of alternative techniques and the influence of clinical status.LondonKing’s College1999
     [Google Scholar]
  18. Tolou-GhamariZ. PalizbanA.A. TredgerJ.M. Modelling tacrolimus auc in acute and chronic liver disease immediately after transplant. transplantationsmedizin.Organ der Deutschen Transplantationsgesellschaft2004162109111
     [Google Scholar]
  19. Tolou-GhamariZ. PalizbanA.A. WendonJ. TredgerJ.M. Pharmacokinetics of tacrolimus immediately after liver transplantation. transplantationsmedizin.Organ der Deutschen Transplantationsgesellschaft2004162112116
     [Google Scholar]
  20. RothG.A. MensahG.A. JohnsonC.O. AddoloratoG. AmmiratiE. BaddourL.M. BarengoN.C. BeatonA.Z. BenjaminE.J. BenzigerC.P. BonnyA. BrauerM. BrodmannM. CahillT.J. CarapetisJ. CatapanoA.L. ChughS.S. CooperL.T. CoreshJ. CriquiM. DeCleeneN. EagleK.A. Emmons-BellS. FeiginV.L. Fernández-SolàJ. FowkesG. GakidouE. GrundyS.M. HeF.J. HowardG. HuF. InkerL. KarthikeyanG. KassebaumN. KoroshetzW. LavieC. Lloyd-JonesD. LuH.S. MirijelloA. TemesgenA.M. MokdadA. MoranA.E. MuntnerP. NarulaJ. NealB. NtsekheM. Moraes de OliveiraG. OttoC. OwolabiM. PrattM. RajagopalanS. ReitsmaM. RibeiroA.L.P. RigottiN. RodgersA. SableC. ShakilS. Sliwa-HahnleK. StarkB. SundströmJ. TimpelP. TleyjehI.M. ValgimigliM. VosT. WheltonP.K. YacoubM. ZuhlkeL. MurrayC. FusterV. RothG.A. MensahG.A. JohnsonC.O. AddoloratoG. AmmiratiE. BaddourL.M. BarengoN.C. BeatonA. BenjaminE.J. BenzigerC.P. BonnyA. BrauerM. BrodmannM. CahillT.J. CarapetisJ.R. CatapanoA.L. ChughS. CooperL.T. CoreshJ. CriquiM.H. DeCleeneN.K. EagleK.A. Emmons-BellS. FeiginV.L. Fernández-SolaJ. FowkesF.G.R. GakidouE. GrundyS.M. HeF.J. HowardG. HuF. InkerL. KarthikeyanG. KassebaumN.J. KoroshetzW.J. LavieC. Lloyd-JonesD. LuH.S. MirijelloA. MisganawA.T. MokdadA.H. MoranA.E. MuntnerP. NarulaJ. NealB. NtsekheM. OliveiraG.M.M. OttoC.M. OwolabiM.O. PrattM. RajagopalanS. ReitsmaM.B. RibeiroA.L.P. RigottiN.A. RodgersA. SableC.A. ShakilS.S. SliwaK. StarkB.A. SundströmJ. TimpelP. TleyjehI.I. ValgimigliM. VosT. WheltonP.K. YacoubM. ZuhlkeL.J. Abbasi-KangevariM. AbdiA. AbediA. AboyansV. AbrhaW.A. Abu-GharbiehE. AbushoukA.I. AcharyaD. AdairT. AdebayoO.M. AdemiZ. AdvaniS.M. AfshariK. AfshinA. AgarwalG. AgasthiP. AhmadS. AhmadiS. AhmedM.B. AjiB. AkaluY. Akande-SholabiW. AkliluA. AkunnaC.J. AlahdabF. Al-EyadhyA. AlhabibK.F. AlifS.M. AlipourV. AljunidS.M. AllaF. Almasi-HashianiA. AlmustanyirS. Al-RaddadiR.M. AmegahA.K. AminiS. AminorroayaA. AmuH. AmugsiD.A. AncuceanuR. AnderliniD. AndreiT. AndreiC.L. Ansari-MoghaddamA. AntenehZ.A. AntonazzoI.C. AntonyB. AnwerR. AppiahL.T. ArablooJ. ÄrnlövJ. ArtantiK.D. AtaroZ. AusloosM. Avila-BurgosL. AwanA.T. AwokeM.A. AyeleH.T. AyzaM.A. AzariS. BD.B. BaheiraeiN. BaigA.A. BakhtiariA. BanachM. BanikP.C. BaptistaE.A. BarbozaM.A. BaruaL. BasuS. BediN. BéjotY. BennettD.A. BensenorI.M. BermanA.E. BezabihY.M. BhagavathulaA.S. BhaskarS. BhattacharyyaK. BijaniA. BikbovB. BirhanuM.M. BoloorA. BrantL.C. BrennerH. BrikoN.I. ButtZ.A. Caetano dos SantosF.L. CahillL.E. Cahuana-HurtadoL. CámeraL.A. Campos-NonatoI.R. Cantu-BritoC. CarJ. CarreroJ.J. CarvalhoF. Castañeda-OrjuelaC.A. Catalá-LópezF. CerinE. CharanJ. ChattuV.K. ChenS. ChinK.L. ChoiJ-Y.J. ChuD-T. ChungS-C. CirilloM. CoffeyS. ContiS. CostaV.M. CundiffD.K. DadrasO. DagnewB. DaiX. DamascenoA.A.M. DandonaL. DandonaR. DavletovK. De la Cruz-GóngoraV. De la HozF.P. De NeveJ-W. Denova-GutiérrezE. Derbew MollaM. DersehB.T. DesaiR. DeuschlG. DharmaratneS.D. DhimalM. DhunganaR.R. DianatinasabM. DiazD. DjalaliniaS. DokovaK. DouiriA. DuncanB.B. DuraesA.R. EaganA.W. EbtehajS. EftekhariA. EftekharzadehS. EkholuenetaleM. El NahasN. ElgendyI.Y. ElhadiM. El-JaafaryS.I. EsteghamatiS. EtissoA.E. EyawoO. FadhilI. FaraonE.J.A. FarisP.S. FarwatiM. FarzadfarF. FernandesE. Fernandez PrendesC. FerraraP. FilipI. FischerF. FloodD. FukumotoT. GadM.M. GaidhaneS. GanjiM. GargJ. GebreA.K. GebregiorgisB.G. GebregzabiherK.Z. GebremeskelG.G. GetacherL. ObsaA.G. GhajarA. GhashghaeeA. GhithN. GiampaoliS. GilaniS.A. GillP.S. GillumR.F. GlushkovaE.V. GnedovskayaE.V. GolechhaM. GonfaK.B. GoudarzianA.H. GoulartA.C. GuadamuzJ.S. GuhaA. GuoY. GuptaR. HachinskiV. Hafezi-NejadN. HaileT.G. HamadehR.R. HamidiS. HankeyG.J. HargonoA. HartonoR.K. HashemianM. HashiA. HassanS. HassenH.Y. HavmoellerR.J. HayS.I. HayatK. HeidariG. HerteliuC. HollaR. HosseiniM. HosseinzadehM. HostiucM. HostiucS. HousehM. HuangJ. HumayunA. IavicoliI. IbenemeC.U. IbitoyeS.E. IlesanmiO.S. IlicI.M. IlicM.D. IqbalU. IrvaniS.S.N. IslamS.M.S. IslamR.M. IsoH. IwagamiM. JainV. JavaheriT. JayapalS.K. JayaramS. JayawardenaR. JeemonP. JhaR.P. JonasJ.B. JonnagaddalaJ. JoukarF. JozwiakJ.J. JürissonM. KabirA. KahlonT. KalaniR. KalhorR. KamathA. KamelI. KandelH. KandelA. KarchA. KasaA.S. KatotoP.D.M.C. KayodeG.A. KhaderY.S. KhammarniaM. KhanM.S. KhanM.N. KhanM. KhanE.A. KhatabK. KibriaG.M.A. KimY.J. KimG.R. KimokotiR.W. KisaS. KisaA. KivimäkiM. KolteD. KoolivandA. KorshunovV.A. Koulmane LaxminarayanaS.L. KoyanagiA. KrishanK. KrishnamoorthyV. Kuate DefoB. Kucuk BicerB. KulkarniV. KumarG.A. KumarN. KurmiO.P. KusumaD. KwanG.F. La VecchiaC. LaceyB. LallukkaT. LanQ. LasradoS. LassiZ.S. LauriolaP. LawrenceW.R. LaxmaiahA. LeGrandK.E. LiM-C. LiB. LiS. LimS.S. LimL-L. LinH. LinZ. LinR-T. LiuX. LopezA.D. LorkowskiS. LotufoP.A. LugoA. MN.K. MadottoF. MahmoudiM. MajeedA. MalekzadehR. MalikA.A. MamunA.A. ManafiN. MansourniaM.A. MantovaniL.G. MartiniS. MathurM.R. MazzagliaG. MehataS. MehndirattaM.M. MeierT. MenezesR.G. MeretojaA. MestrovicT. MiazgowskiB. MiazgowskiT. MichalekI.M. MillerT.R. MirrakhimovE.M. MirzaeiH. MoazenB. MoghadaszadehM. MohammadY. MohammadD.K. MohammedS. MohammedM.A. MokhayeriY. MolokhiaM. MontasirA.A. MoradiG. MoradzadehR. MoragaP. MorawskaL. Moreno VelásquezI. MorzeJ. MubarikS. MuruetW. MusaK.I. NagarajanA.J. NaliniM. NangiaV. NaqviA.A. Narasimha SwamyS. NascimentoB.R. NayakV.C. NazariJ. NazarzadehM. NegoiR.I. Neupane KandelS. NguyenH.L.T. NixonM.R. NorrvingB. NoubiapJ.J. NoutheB.E. NowakC. OdukoyaO.O. OgboF.A. OlagunjuA.T. OrruH. OrtizA. OstroffS.M. PadubidriJ.R. PalladinoR. PanaA. Panda-JonasS. ParekhU. ParkE-C. ParviziM. Pashazadeh KanF. PatelU.K. PathakM. PaudelR. PepitoV.C.F. PerianayagamA. PericoN. PhamH.Q. PilgrimT. PiradovM.A. PishgarF. PodderV. PolibinR.V. PourshamsA. PribadiD.R.A. RabieeN. RabieeM. RadfarA. RafieiA. RahimF. Rahimi-MovagharV. Ur RahmanM.H. RahmanM.A. RahmaniA.M. RakovacI. RamP. RamalingamS. RanaJ. RanasingheP. RaoS.J. RathiP. RawalL. RawasiaW.F. RawassizadehR. RemuzziG. RenzahoA.M.N. RezapourA. RiahiS.M. Roberts-ThomsonR.L. RoeverL. RohloffP. RomoliM. RoshandelG. RwegereraG.M. SaadatagahS. Saber-AyadM.M. SabourS. SaccoS. SadeghiM. Saeedi MoghaddamS. SafariS. SahebkarA. SalehiS. SalimzadehH. SamaeiM. SamyA.M. SantosI.S. Santric-MilicevicM.M. SarrafzadeganN. SarveazadA. SathishT. SawhneyM. SaylanM. SchmidtM.I. SchutteA.E. SenthilkumaranS. SepanlouS.G. ShaF. ShahabiS. ShahidI. ShaikhM.A. ShamaliM. ShamsizadehM. ShawonM.S.R. SheikhA. ShigematsuM. ShinM-J. ShinJ.I. ShiriR. ShiueI. ShuvalK. SiabaniS. SiddiqiT.J. SilvaD.A.S. SinghJ.A. MtechA.S. SkryabinV.Y. SkryabinaA.A. SoheiliA. SpurlockE.E. StockfeltL. StorteckyS. StrangesS. Suliankatchi AbdulkaderR. TadbiriH. TadesseE.G. TadesseD.B. TajdiniM. TariqujjamanM. TeklehaimanotB.F. TemsahM-H. TesemaA.K. ThakurB. ThankappanK.R. ThaparR. ThriftA.G. TimalsinaB. TonelliM. TouvierM. Tovani-PaloneM.R. TripathiA. TripathyJ.P. TruelsenT.C. TsegayG.M. TsegayeG.W. TsilimparisN. TusaB.S. TyrovolasS. UmapathiK.K. UnimB. UnnikrishnanB. UsmanM.S. VaduganathanM. ValdezP.R. VasankariT.J. VelazquezD.Z. VenketasubramanianN. VuG.T. VujcicI.S. WaheedY. WangY. WangF. WeiJ. WeintraubR.G. WeldemariamA.H. WestermanR. WinklerA.S. WiysongeC.S. WolfeC.D.A. WubishetB.L. XuG. YadollahpourA. YamagishiK. YanL.L. YandrapalliS. YanoY. YatsuyaH. YeheyisT.Y. YeshawY. YilgwanC.S. YonemotoN. YuC. YusefzadehH. ZachariahG. ZamanS.B. ZamanM.S. ZamanianM. ZandR. ZandifarA. ZarghiA. ZastrozhinM.S. ZastrozhinaA. ZhangZ-J. ZhangY. ZhangW. ZhongC. ZouZ. ZunigaY.M.H. MurrayC.J.L. FusterV. Global burden of cardiovascular diseases and risk factors, 1990–2019.J. Am. Coll. Cardiol.202076252982302110.1016/j.jacc.2020.11.01033309175
     [Google Scholar]
  21. MaaikeA. SikmaM.A. HunaultC.C. KirkelsJ.H. VerhaarM.C. KeseciogluJ. de LangeD.W. Association of whole blood tacrolimus concentrations with kidney injury in heart transplantation patients.Eur. J. Drug Metab. Pharmacokinet.201843331132029236211
     [Google Scholar]
  22. MorizawaY. SatohH. AraiM. IwasaS. SatoA. FujimotoK. Association between nonadherence and transient hyperuricemia in pediatric kidney transplantation.Transplant. Proc.202355112913310.1016/j.transproceed.2022.09.03336581508
     [Google Scholar]
  23. BansalN. EverittM.D. NandiD. SpinnerJ. ConwayJ. MagnettaD.A. ProfitaE.L. TownsendM. AlejosJ.C. DeshpandeS.R. Clinical approach to acute cellular rejection from the pediatric heart transplant society.Pediatr. Transplant.2022268e1439310.1111/petr.1439336377327
     [Google Scholar]
  24. BalceracA. BihanK. PsimarasD. Lebrun-VignesB. SalemJ.E. WeissN. Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study.J. Neurol.2023270297598510.1007/s00415‑022‑11450‑y36329183
     [Google Scholar]
  25. CosteG. ChabanneC. TronC. LelongB. VerdierM.C. RousselM. Le GallF. TurlinB. Desille-DugastM. FlécherE. LaviolleB. LemaitreF. Blood, cellular, and tissular calcineurin inhibitors pharmacokinetic–pharmacodynamic relationship in heart transplant recipients: The INTRACAR study.Ther. Drug Monit.202345222923510.1097/FTD.000000000000102536006706
     [Google Scholar]
  26. SöderlundC. RådegranG. Immunosuppressive therapies after heart transplantation: The balance between under- and over-immunosuppression.Transplant. Rev.201529318118910.1016/j.trre.2015.02.00525812489
     [Google Scholar]
  27. KimI.C. YounJ.C. KobashigawaJ.A. KobashigawaJ.A. The past, present and future of heart transplantation.Korean Circ. J.201848756559010.4070/kcj.2018.018929968430
     [Google Scholar]
  28. Blanca Martínez PérezA. López SuárezA. Rodríguez RodríguezJ. Sobrino MárquezJ.M. Lage GalléE. Medication adherence in patients who undergo cardiac transplantation.Transplant. Proc.201345103662366410.1016/j.transproceed.2013.11.00624314989
     [Google Scholar]
  29. MasoudiF.A. KrumholzH.M. Polypharmacy and comorbidity in heart failure.BMJ2003327741451351410.1136/bmj.327.7414.51312958085
     [Google Scholar]
  30. YangF.C. ChenH.M. HuangC.M. HsiehP.L. WangS.S. ChenC.M. The difficulties and needs of organ transplant recipients during postoperative care at home: A systematic review.Int. J. Environ. Res. Public Health20201716579810.3390/ijerph1716579832796529
     [Google Scholar]
  31. PeretzD. OnN.H. MillerD. KimR. FranklinC. DascalR. KnowlesC. MinukG.Y. Pharmacokinetics of a once‐daily tacrolimus formulation in first nations and caucasian liver transplant recipients.Transpl. Int.202134112266227310.1111/tri.1399734318518
     [Google Scholar]
  32. LiY. JingQ. WangB. WangX. LiJ. QiaoS. ChenS. AngiolilloD.J. HanY. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. rationale and design of the opt-birisk double-blinded, placebo-controlled randomized trial.Am. Heart J.20202281710.1016/j.ahj.2020.07.00532739652
     [Google Scholar]
  33. ZhouZ.X. YinX.D. ZhangY. ShaoQ.H. MaoX.Y. HuW.J. ShenY.L. ZhaoB. LiZ.L. Antifungal drugs and drug-induced liver injury: A real-world study leveraging the fda adverse event reporting system database.Front. Pharmacol.20221389133610.3389/fphar.2022.89133635571077
     [Google Scholar]
  34. KoflaG. RuhnkeM. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis:Review of the literature.Eur. J. Med. Res.201116415916610.1186/2047‑783X‑16‑4‑15921486730
     [Google Scholar]
  35. DharR. Neurologic complications of transplantation.Neurocrit. Care201828141110.1007/s12028‑017‑0387‑628251577
     [Google Scholar]
  36. RobertL. PageIIR.L. MillerG.G. LindenfeldJ. GeraldineG. Drug therapy in the heart transplant recipient.Circulation2005111230239
     [Google Scholar]
  37. RiviniusR. HelmschrottM. RahmA.K. DarcheF.F. ThomasD. BrucknerT. DoeschA.O. EhlermannP. KatusH.A. ZitronE. Combined amiodarone and digitalis therapy before heart transplantation is associated with increased post‐transplant mortality.ESC Heart Fail.2020752082209210.1002/ehf2.1280732608191
     [Google Scholar]
  38. ChengC.W. HendricksonJ.E. TormeyC.A. Davinder SidhuD. Therapeutic plasma exchange and its impact on drug levels: An aclps critical review.Am J Clin Pathol2017148319019810.1093/ajcp/aqx056
     [Google Scholar]
  39. ShepardP.W. St LouisE.K. Seizure treatment in transplant patients.Curr. Treat. Options Neurol.201214433234710.1007/s11940‑012‑0180‑y22660960
     [Google Scholar]
  40. SawhneyH. GillS.S. Renal transplant recipient seizure practical management.World J. Nephrol.2020911810.5527/wjn.v9.i1.132742951
     [Google Scholar]
  41. JantzA.S. PatelS.J. SukiW.N. KnightR.J. BhimarajA. GaberA.O. Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients.Case Rep. Transplant.201320131610.1155/2013/37526323844312
     [Google Scholar]
  42. BeezerJ. Al HatrushiM. HusbandA. KurdiA. ForsythP. Polypharmacy definition and prevalence in heart failure: A systematic review.Heart Fail. Rev.202227246549210.1007/s10741‑021‑10135‑434213753
     [Google Scholar]
  43. AhmadianE. Zununi VahedS. MammadovaS. AbediazarS. Immunosuppressant management in renal transplant patients with COVID-19.BioMed Res. Int.202120211810.1155/2021/931872534692845
     [Google Scholar]
  44. OomenL. Bootsma-RobroeksC. CornelissenE. WallL. FeitzW. Pearls and pitfalls in pediatric kidney transplantation after 5 decades.Front Pediatr.20221085663010.3389/fped.2022.85663035463874
     [Google Scholar]
  45. Tolou-GhamariZ. PalizbanA. GharaviM. Cyclosporin trough concentration-rejection relationship after kidney transplantation.Indian J. Pharmacol.2003356395396
     [Google Scholar]
  46. Tolou-GhamariZ. MortazaviM. PalizbanA.A. NajafiM.R. The investigation of correlation between iminoral concentration and neurotoxic levels after kidney transplantation.Adv. Biomed. Res.2015410.4103/2277‑9175.151876
     [Google Scholar]
  47. Tolou-GhamariZ SaneiB Prograf concentrations in liver transplantation: Correlation with headache and other neurotoxic complications.Thrita201651
     [Google Scholar]
  48. Tolou-GhamariZ. PalizbanA.A. Laboratory monitoring of cyclosporine pre-dose concentration (c 0) after kidney transplantation in isfahan.IJMS20032828185
     [Google Scholar]
  49. KniepeissD. RennerW. TrummerO. WagnerD. WaslerA. KhoschsorurG.A. Truschnig-WildersM. TscheliessniggK.H. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.Clin. Transplant.201125114615010.1111/j.1399‑0012.2009.01198.x20041908
     [Google Scholar]
  50. PatelJ.K. KobashigawaJ.A. Tacrolimus in heart transplant recipients: An overview.BioDrugs200721313914310.2165/00063030‑200721030‑0000117516709
     [Google Scholar]
  51. McCormackP.L. KeatingG.M. Tacrolimus.Drugs200666172269227910.2165/00003495‑200666170‑0001017137409
     [Google Scholar]
  52. GijsenV. MitalS. van SchaikR.H. SoldinO.P. SoldinS.J. van der HeidenI.P. NulmanI. KorenG. de WildtS.N. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.J. Heart Lung Transplant.201130121352135910.1016/j.healun.2011.08.00121930396
     [Google Scholar]
  53. van GelderT. BalkA.H. ZietseR. HesseC. MochtarB. WeimarW. Renal insufficiency after heart transplantation: A case-control study.Nephrol. Dial. Transplant.19981392322232610.1093/ndt/13.9.23229761516
     [Google Scholar]
  54. JiaY. MengX. LiY. XuC. ZengW. JiaoY. HanW. Optimal sampling time point for cyclosporin a concentration monitoring in heart transplant recipients.Exp. Ther. Med.20181654265427010.3892/etm.2018.671130402164
     [Google Scholar]
  55. KatadaY. NakagawaS. ItoharaK. SuzukiT. KatoR. EndoH. Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation.J. Pharm. Health Care Sci.2022812510.1186/s40780‑022‑00256‑9
     [Google Scholar]
  56. De GregoriS. De SilvestriA. CattadoriB. RapagnaniA. AlbertiniR. NovelloE. Therapeutic drug monitoring of tacrolimus-personalized therapy in heart transplantation: New strategies and preliminary results in endomyocardial biopsies.Pharmaceutics2022146124710.3390/pharmaceutics14061247
     [Google Scholar]
  57. Toro-TrujilloE. GarciaE. Garcia-PeñaA.A. Muñoz-VelandiaO.M. MariñoA. Factors related to the acute cellular rejection during the first year after heart transplant.Transplant. Proc.201850103715371910.1016/j.transproceed.2018.08.04130577261
     [Google Scholar]
  58. GrimmM. RinaldiM. YonanN.A. ArpesellaG. Arizón Del PradoJ.M. PulpónL.A. VillemotJ.P. FrigerioM. Rodriguez LambertJ.L. Crespo-LeiroM.G. AlmenarL. DuveauD. Ordonez-FernandezA. GandjbakhchJ. MaccheriniM. LauferG. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large european trial.Am. J. Transplant.2006661387139710.1111/j.1600‑6143.2006.01300.x16686762
     [Google Scholar]
  59. TonshoM. MichelS. AhmedZ. AlessandriniA. MadsenJ.C. Heart transplantation: Challenges facing the field.Cold Spring Harb. Perspect. Med.201445a01563610.1101/cshperspect.a01563624789875
     [Google Scholar]
  60. DoeschA. HelmschrottM. BeckendorfJ. AkyolC. RuhparwarA. SchmackB. ErbelC. GleissnerC. AkhavanpoorM. EhlermannP. BrucknerT. KatusH. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen.Drug Des. Devel. Ther.201481307131410.2147/DDDT.S6854225246772
     [Google Scholar]
  61. PeledY. LaveeJ. AradM. ShemeshY. KatzM. KassifY. AsherE. ElianD. Har-ZahavY. GoldenbergI. FreimarkD. The impact of gender mismatching on early and late outcomes following heart transplantation.ESC Heart Fail.201741313910.1002/ehf2.1210728217310
     [Google Scholar]
  62. GuptaT. KrimS.R. Cardiac transplantation: Update on a road less traveled.Ochsner J.201919436937710.31486/toj.19.002231903061
     [Google Scholar]
  63. BifulcoO. BottioT. CaraffaR. CarrozziniM. GuarientoA. BejkoJ. FedrigoM. CastellaniC. ToscanoG. LorenzoniG. TarziaV. GregoriD. CardilloM. PuotiF. FeltrinG. AngeliniA. GerosaG. Marginal versus standard donors in heart transplantation: Proper selection means heart transplant benefit.J. Clin. Med.2022119266510.3390/jcm1109266535566789
     [Google Scholar]
  64. FujitaR. TakabayashiK. IwatsuK. MatsumuraK. IkedaT. KitaguchiS. NoharaR. P6360Prognostic value of polypharmacy in patients with heart failure.Eur. Heart J.2019401)(1ehz746.095610.1093/eurheartj/ehz746.0956
     [Google Scholar]
  65. Gomis-PastorM. MirabetS. RoigE. LopezL. BrossaV. Galvez-TugasE. Rodriguez-MurphyE. FeliuA. OntiverosG. Garcia-CuyàsF. SalazarA. ManguesM.A. Interdisciplinary mobile health model to improve clinical care after heart transplantation: Implementation strategy study.JMIR Cardio202041e1906510.2196/1906533231557
     [Google Scholar]
/content/journals/chamc/10.2174/1871525721666230726150021
Loading
Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation
Cardiovasc. Hematol. Agents Med. Chem. 22, 106 (2024); https://doi.org/10.2174/1871525721666230726150021
/content/journals/chamc/10.2174/1871525721666230726150021
/content/journals/chamc/10.2174/1871525721666230726150021
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cyclosporin; detection; Heart; immunosuppressive; pharmacotherapy; tacrolimus; transplant

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test